NHS patients to get easier access to MS pill after NICE rethinkPatients in England are to get easier access to Merck KGaA’s multiple sclerosis drug Mavenclad after NICE dropped Share XNHS patients to get easier access to MS pill after NICE rethinkhttps://pharmaphorum.com/news/nhs-patients-to-get-easier-access-to-ms-pill-after-nice-rethink/
Brisk trade in risky three-drug ‘bet’ option after BMS/Celgene mergerBristol-Myers Squibb’s $74 billion merger with Celgene went ahead this week after clearance from US competition regulators, and Share XBrisk trade in risky three-drug ‘bet’ option after BMS/Celgene mergerhttps://pharmaphorum.com/news/celgene-shareholders/
Mavenclad helps Merck shrug off Rebif decline in MSAccelerating sales of Merck KGaA’s oral multiple sclerosis therapy Mavenclad helped the company to a double-digit rise in Share XMavenclad helps Merck shrug off Rebif decline in MShttps://pharmaphorum.com/news/mavenclad-helps-merck-shrug-off-rebif-decline-in-ms/
NICE backs NHS funding for two cannabis-based drugs for first timeNICE has recommended two of GW Pharma’s cannabis-based medicines, the first time that medicines derived from the plant Share XNICE backs NHS funding for two cannabis-based drugs for first timehttps://pharmaphorum.com/news/nice-includes-bayer-gws-cannabis-based-sativex-in-ms-guideline-for-first-time/
Sanofi settles dispute with Genzyme investors over MS drugSanofi has settled a long-running dispute with shareholders in the biotech Genzyme, who claimed the big pharma deliberately Share XSanofi settles dispute with Genzyme investors over MS drughttps://pharmaphorum.com/news/sanofi-settles-dispute-with-genzyme-investors-over-ms-drug/
Biogen bags FDA okay for Tecfidera follow-up VumerityBiogen’s multiple sclerosis franchise has been handed a boost with the US approval of Vumerity, a follow-up to Share XBiogen bags FDA okay for Tecfidera follow-up Vumerityhttps://pharmaphorum.com/news/biogen-fda-tecfidera-vumerity-ms/
Getting MS diagnosis rightMS advocate Trishna Bharadia explains how diagnosis needs to change and why pharma shouldn’t be using the word Share XGetting MS diagnosis righthttps://pharmaphorum.com/views-analysis-patients/getting-ms-diagnosis-right/
Janssen’s MS pill outshines Sanofi’s Aubagio in phase 3 trialJohnson & Johnson’s Janssen unit has announced phase 3 results showing that its ponesimod tablet outperformed Sanofi’s Aubagio Share XJanssen’s MS pill outshines Sanofi’s Aubagio in phase 3 trialhttps://pharmaphorum.com/news/janssens-ms-pill-outshines-sanofis-aubagio-in-phase-3-trial/
Novartis strikes marketing deal for Polpharma’s potential Tysabri biosimilarNovartis’ biosimilars and generics arm Sandoz has struck a deal with Polpharma Biologics to market a proposed biosimilar Share XNovartis strikes marketing deal for Polpharma’s potential Tysabri biosimilarhttps://pharmaphorum.com/news/novartis-strikes-marketing-deal-for-polpharmas-potential-tysabri-biosimilar/
